Definition: Post-inﬂammatory hyperpigmentation is seen following acneiform eruption or other causes of skin inﬂammation such as eczema or an inﬂamed sebaceous cyst. Sun exposure aggravates the hyperpigmentation.1
Onset: More than 8 weeks after treatment initiation.
Resolution: Only within months of completion of EGFRI treatment.
- L81.8 Other specified disorders of pigmentation.
- Y43.8 Other drugs, medicaments and biological primarily systemic substances causing adverse effects in therapeutic use, not elsewhere classified.
Hyperpigmentation covering <10% BSA; no psychosocial impact.
Hyperpigmentation covering >10% BSA; associated psychosocial impact.
Typical clinical presentations of hyperpigmentation can be viewed at the bottom of the page.
1Segaert S & Van Cutsem E. Ann Oncol 2005; 16: 1425-1433.
2European Medicine Agency. Tarceva® (erlotinib) Summary of Product Characteristics 2009.
3European Medicine Agency. Iressa® (gefitinib) Summary of Product Characteristics 2009.
4European Medicine Agency. Erbitux® (cetuximab) Summary of Product Characteristics 2009.
5European Medicine Agency. Vectibix® (panitumumab) Summary of Product Characteristics 2009.
6European Medicine Agency. Tyverb® (lapatinib) Summary of Product Characteristics 2010.